ProCE Banner Series

Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time

This 1.5-hour interactive satellite symposium held in conjunction with the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, will provide perspectives from experts who serve on the National Comprehensive Cancer Network CLL/SLL panel on the latest clinical developments and clinical guidance on recent data and emerging treatment advances in the personalization of care of patients with CLL/SLL.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for oncologists, physician associates, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL.

All Events

Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time

Past Events

June

01

2024

6:30 PM - 8:30 PM Central Time (CT)

In-person

Hilton Chicago, 720 S Michigan Ave., Chicago, Illinois 60605

7:00 PM - 8:30 PM Central Time (CT)

Virtual

June

20

2024

5:00 PM - 7:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

ProCE Banner Faculty
Farrukh Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Shuo Ma, MD, PhD

Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Topics

Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in the potential clinical applications of guideline-recommended therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Target Audience
This educational program is intended for oncologists, physician associates, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action
  • Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal  sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)
  • Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 2.0 contact hours. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-24-079-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly. Supported by an independent medical education grant from AbbVie.